WHAT KILLS CANCER PATIENTS: THE DISEASE OR THE TREATMENT?

Cancer is the second leading cause of death in the United States. That reality raises an urgent follow-up: when people with cancer die, how much is the disease and how much is the treatment or the damage it caused?

In oncology, the injuries are predictable. The tracking isn’t.

If this were OSHA, every harm would be logged. In cancer care, most aren’t.

Modern cancer care saves lives and causes harm, a lot of harm. Some are foreseeable, sometimes common: organ failure, stroke, treatment-triggered death, secondary cancer. Yet unlike other high-risk industries, oncology rarely tracks or discloses these harms systematically.

A widely cited analysis argues that medical error may be the third leading cause of death in the United States. Even critics agree on the core issue: our data systems and death certificates do not capture care-caused deaths well. In cancer, attribution becomes blurred especially when treatment-related harm is recorded as disease progression.

So here’s the question: do people die from the cancer or from the treatment and its downstream effects? The honest answer is both. The problem is: we don’t measure the difference well enough to inform patients properly.

After spending 35 years in occupational safety and health where every injury is recorded, logged, and investigated I entered oncology as a patient. What I found was staggering. In OSHA, prevention is the priority. Injuries are classified, tracked, and used to improve systems. In cancer care, treatment comes first. Harm, if recorded at all, is often buried in trials, misattributed, or ignored. These are two systems that don’t speak the same language.

I’m a two-time head and neck cancer survivor. I received cisplatin and radiation and now live with long-term cognitive impairment that was dismissed as “chemo fog.” More than five years after treatment, I discovered on my own that I am at elevated risk for stroke due to radiation-induced carotid artery damage. That risk was never explained to me. This isn’t rare. It’s systemic.

Even during treatment, the risks are significant. Modern clinical trials show that chemoradiation for head and neck cancers carries a 1–3% treatment-related death rate. In real-world settings, where patients are older and more complex, that rate can be higher. For patients receiving palliative chemotherapy, early mortality within 30 days is tracked as a safety signal. In some cases, it is not the cancer that kills first—but the treatment: infections, organ failure, or immune complications.

Years after treatment, the risks continue. Radiation to the neck significantly increases the risk of carotid artery stenosis and stroke. Multiple studies recommend long-term ultrasound surveillance beginning a few years after treatment. Yet many patients are never informed, and no standardized survivorship protocols exist to monitor this risk.

Even when harm occurs, it is often not properly recorded. A death caused by treatment toxicity or delayed injury may still be classified as a “cancer death.” There is no standard way to record treatment-related death on a death certificate. Cancer registries track diagnosis and survival but not treatment injury. The FDA’s adverse event reporting system is voluntary and widely underreported. The result: treatment-related harm remains largely invisible.

Diagnostic error is another systemic risk. A 2024 study estimated that nearly 800,000 Americans each year are seriously harmed or die from major diagnostic errors. These events are rarely captured in national mortality data. In 2016, a widely cited BMJ study suggested that medical error would rank as the third leading cause of death in the United States if properly recorded. Even critics of the study agree on the central issue: our reporting systems conceal more than they reveal.

Head and neck radiation significantly increases stroke risk by damaging the carotid arteries. This is well documented in peer-reviewed research. Some institutions recommend routine screening beginning 2–5 years after treatment. But most survivorship plans omit it entirely. In any OSHA-regulated environment, failing to disclose and monitor a known risk like this would be a serious violation. In cancer care, it is standard practice.

In workplace safety, every serious injury is logged, who it happened to, what caused it, how severe it was, and what was done to prevent recurrence. These records feed into national systems that drive prevention and accountability. Oncology has no equivalent.

We need a safety model for cancer care. A national Treatment Harm Log to document therapies, complications, and outcomes. A survivorship “Critical Risks” checklist reviewed at key stages of care. Death certificates that include treatment-related contribution. Mandatory reporting of serious adverse events. A Patient Harm Index (PHI), similar to OSHA’s Experience Modification Rating, to measure institutional harm rates. And legal accountability for preventable treatment-related injury.

This is not about assigning blame. It is about acknowledging reality. Treatment saves lives—but it also causes harm, sometimes severe and sometimes fatal. We cannot eliminate all risk. But we can track it. We can disclose it. And we can design systems that learn from it.

Cancer didn’t kill me. The treatment didn’t either. But parts of me were lost along the way risks no one warned me I’d be taking. Patients deserve a system that tracks harm with the same rigor it tracks hope.